12/12
08:06 am
olma
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at Citigroup Inc. from $21.00 to $60.00. They now have a "buy" rating on the stock.
Low
Report
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at Citigroup Inc. from $21.00 to $60.00. They now have a "buy" rating on the stock.
12/11
01:19 pm
olma
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $45.00 to $48.00. They now have an "outperform" rating on the stock.
Low
Report
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $45.00 to $48.00. They now have an "outperform" rating on the stock.
12/11
12:31 pm
olma
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $26.00 to $38.00. They now have a "buy" rating on the stock.
Medium
Report
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $26.00 to $38.00. They now have a "buy" rating on the stock.
12/11
10:38 am
olma
Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT [Yahoo! Finance]
Medium
Report
Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT [Yahoo! Finance]
12/11
08:07 am
olma
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at HC Wainwright from $36.00 to $45.00. They now have a "buy" rating on the stock.
Medium
Report
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at HC Wainwright from $36.00 to $45.00. They now have a "buy" rating on the stock.
12/10
09:08 am
olma
Roche boosts Olema after additional late-stage trial data for breast cancer drug [Seeking Alpha]
Medium
Report
Roche boosts Olema after additional late-stage trial data for breast cancer drug [Seeking Alpha]
12/2
04:30 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/21
06:11 pm
olma
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
Medium
Report
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
11/21
04:30 pm
olma
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
Medium
Report
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
11/21
01:20 pm
olma
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $26.00. They now have a "buy" rating on the stock.
Medium
Report
Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $26.00. They now have a "buy" rating on the stock.
11/20
04:11 pm
olma
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
Medium
Report
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
11/20
04:01 pm
olma
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Medium
Report
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/19
11:43 am
olma
Olema Pharmaceuticals: Shares Double On Roche's MBC Data - I Preach Caution [Seeking Alpha]
High
Report
Olema Pharmaceuticals: Shares Double On Roche's MBC Data - I Preach Caution [Seeking Alpha]
11/19
07:00 am
olma
Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock
Medium
Report
Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock
11/19
06:37 am
olma
Olema Pharmaceuticals (OLMA) Rethinks Competitive Edge After Roche's Breast Cancer Trial Success [Yahoo! Finance]
Medium
Report
Olema Pharmaceuticals (OLMA) Rethinks Competitive Edge After Roche's Breast Cancer Trial Success [Yahoo! Finance]
11/18
04:55 pm
olma
Olema Pharmaceuticals plans public offering of stock, pre-funded warrants; shares down [Seeking Alpha]
Medium
Report
Olema Pharmaceuticals plans public offering of stock, pre-funded warrants; shares down [Seeking Alpha]
11/18
04:51 pm
olma
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
11/10
08:18 am
olma
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results [Yahoo! Finance]
Medium
Report
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results [Yahoo! Finance]
11/10
07:33 am
olma
Olema Pharmaceuticals GAAP EPS of -$0.49 [Seeking Alpha]
Medium
Report
Olema Pharmaceuticals GAAP EPS of -$0.49 [Seeking Alpha]
11/10
07:00 am
olma
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
Medium
Report
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
11/4
04:30 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/3
04:30 pm
olma
Olema Oncology to Participate in Upcoming Investor Conferences
Low
Report
Olema Oncology to Participate in Upcoming Investor Conferences
10/30
04:30 pm
olma
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
Medium
Report
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
10/20
08:06 am
olma
Olema Pharmaceuticals (NASDAQ:OLMA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Olema Pharmaceuticals (NASDAQ:OLMA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/20
08:06 am
olma
Olema Pharmaceuticals (NASDAQ:OLMA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
High
Report
Olema Pharmaceuticals (NASDAQ:OLMA) had its "buy" rating reaffirmed by analysts at UBS Group AG.